Which has preferable earnings and valuation, ARGX or NVO?

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 13.08 $1.29B $22.46 39.78 Novo Nordisk A/S $46.80B 4.19 $15.51B $4.26 10.31

Is ARGX or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media favor ARGX or NVO?

In the previous week, Novo Nordisk A/S had 60 more articles in the media than argenex. MarketBeat recorded 67 mentions for Novo Nordisk A/S and 7 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.89 beat argenex's score of 0.77 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 44 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ARGX or SNY?

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 13.08 $1.29B $22.46 39.78 Sanofi $49.35B 2.17 $8.84B $3.58 12.36

Is ARGX or SNY more profitable?

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 44.37% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% Sanofi 16.95% 13.39% 7.58%

Does the media favor ARGX or SNY?

In the previous week, Sanofi had 1 more articles in the media than argenex. MarketBeat recorded 8 mentions for Sanofi and 7 mentions for argenex. argenex's average media sentiment score of 0.77 beat Sanofi's score of 0.29 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, GSK or ARGX?

GSK has higher revenue and earnings than argenex. GSK is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.49 $7.54B $3.85 13.78 argenex $4.25B 13.08 $1.29B $22.46 39.78

Is GSK or ARGX more profitable?

argenex has a net margin of 31.31% compared to GSK's net margin of 17.82%. argenex's return on equity of 44.37% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% argenex 31.31% 44.37% 37.55%

Does the media prefer GSK or ARGX?

In the previous week, GSK had 25 more articles in the media than argenex. MarketBeat recorded 32 mentions for GSK and 7 mentions for argenex. argenex's average media sentiment score of 0.77 beat GSK's score of 0.17 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 14 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ARGX or TAK?

argenex currently has a consensus target price of $1,019.50, indicating a potential upside of 14.10%. Given argenex's stronger consensus rating and higher probable upside, equities analysts plainly believe argenex is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score argenex 0 Sell rating(s) 4 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.92 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media favor ARGX or TAK?

In the previous week, argenex had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 7 mentions for argenex and 6 mentions for Takeda Pharmaceutical. argenex's average media sentiment score of 0.77 beat Takeda Pharmaceutical's score of 0.38 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TEVA or ARGX?

In the previous week, Teva Pharmaceutical Industries had 19 more articles in the media than argenex. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 7 mentions for argenex. Teva Pharmaceutical Industries' average media sentiment score of 1.38 beat argenex's score of 0.77 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 21 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

argenex (ARGX) Competitors

$893.52 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$893.08 -0.43 (-0.05%)

As of 06/12/2026 04:58 PM Eastern

Compare

ARGX vs. NVO, SNY, GSK, TAK, and TEVA

Should you buy argenex stock or one of its competitors? MarketBeat compares argenex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with argenex include Novo Nordisk A/S (NVO), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does argenex compare to Novo Nordisk A/S?

argenex (NASDAQ:ARGX) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	13.08	$1.29B	$22.46	39.78
Novo Nordisk A/S	$46.80B	4.19	$15.51B	$4.26	10.31

argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

argenex presently has a consensus price target of $1,019.50, suggesting a potential upside of 14.10%. Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 49.34%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

60.3% of argenex shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Novo Nordisk A/S had 60 more articles in the media than argenex. MarketBeat recorded 67 mentions for Novo Nordisk A/S and 7 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.89 beat argenex's score of 0.77 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	44 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

argenex beats Novo Nordisk A/S on 9 of the 17 factors compared between the two stocks.

How does argenex compare to Sanofi?

argenex (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

In the previous week, Sanofi had 1 more articles in the media than argenex. MarketBeat recorded 8 mentions for Sanofi and 7 mentions for argenex. argenex's average media sentiment score of 0.77 beat Sanofi's score of 0.29 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	13.08	$1.29B	$22.46	39.78
Sanofi	$49.35B	2.17	$8.84B	$3.58	12.36

argenex currently has a consensus target price of $1,019.50, suggesting a potential upside of 14.10%. Sanofi has a consensus target price of $51.00, suggesting a potential upside of 15.25%. Given Sanofi's higher probable upside, analysts plainly believe Sanofi is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

argenex has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 44.37% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Sanofi	16.95%	13.39%	7.58%

60.3% of argenex shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

argenex beats Sanofi on 12 of the 16 factors compared between the two stocks.

How does argenex compare to GSK?

GSK (NYSE:GSK) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

GSK has higher revenue and earnings than argenex. GSK is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.49	$7.54B	$3.85	13.78
argenex	$4.25B	13.08	$1.29B	$22.46	39.78

argenex has a net margin of 31.31% compared to GSK's net margin of 17.82%. argenex's return on equity of 44.37% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
argenex	31.31%	44.37%	37.55%

15.7% of GSK shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GSK has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

GSK currently has a consensus price target of $53.00, indicating a potential downside of 0.08%. argenex has a consensus price target of $1,019.50, indicating a potential upside of 14.10%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, GSK had 25 more articles in the media than argenex. MarketBeat recorded 32 mentions for GSK and 7 mentions for argenex. argenex's average media sentiment score of 0.77 beat GSK's score of 0.17 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	14 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats GSK on 13 of the 17 factors compared between the two stocks.

How does argenex compare to Takeda Pharmaceutical?

argenex (NASDAQ:ARGX) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

argenex has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

In the previous week, argenex had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 7 mentions for argenex and 6 mentions for Takeda Pharmaceutical. argenex's average media sentiment score of 0.77 beat Takeda Pharmaceutical's score of 0.38 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex currently has a consensus target price of $1,019.50, indicating a potential upside of 14.10%. Given argenex's stronger consensus rating and higher probable upside, equities analysts plainly believe argenex is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

60.3% of argenex shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

argenex has higher earnings, but lower revenue than Takeda Pharmaceutical. argenex is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	13.08	$1.29B	$22.46	39.78
Takeda Pharmaceutical	$28.32B	1.79	$1.27B	$0.39	40.81

argenex has a net margin of 31.31% compared to Takeda Pharmaceutical's net margin of 4.31%. argenex's return on equity of 44.37% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Summary

argenex beats Takeda Pharmaceutical on 15 of the 17 factors compared between the two stocks.

How does argenex compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Teva Pharmaceutical Industries has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Teva Pharmaceutical Industries has higher revenue and earnings than argenex. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.30	$1.41B	$1.33	26.00
argenex	$4.25B	13.08	$1.29B	$22.46	39.78

argenex has a net margin of 31.31% compared to Teva Pharmaceutical Industries' net margin of 9.01%. argenex's return on equity of 44.37% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
argenex	31.31%	44.37%	37.55%

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, indicating a potential upside of 20.83%. argenex has a consensus price target of $1,019.50, indicating a potential upside of 14.10%. Given Teva Pharmaceutical Industries' higher possible upside, research analysts plainly believe Teva Pharmaceutical Industries is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, Teva Pharmaceutical Industries had 19 more articles in the media than argenex. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 7 mentions for argenex. Teva Pharmaceutical Industries' average media sentiment score of 1.38 beat argenex's score of 0.77 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	21 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

Get argenex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARGX vs. The Competition

Export

Metric	argenex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.57B	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	39.78	20.00	24.22	24.42
Price / Sales	13.08	305.69	511.60	109.90
Price / Cash	41.88	53.61	27.48	37.92
Price / Book	7.55	8.32	10.65	6.82
Net Income	$1.29B	$23.94M	$3.57B	$337.56M
7 Day Performance	1.26%	1.84%	0.58%	1.17%
1 Month Performance	11.79%	-0.04%	1.54%	3.16%
1 Year Performance	54.62%	44.82%	25.40%	30.58%

argenex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARGX argenex	4.0745 of 5 stars	$893.52 flat	$1,019.50 +14.1%	+54.6%	$55.57B	$4.25B	39.78	1,863
NVO Novo Nordisk A/S	4.2311 of 5 stars	$41.05 -4.4%	$65.56 +59.7%	-45.1%	$191.82B	$46.80B	9.64	69,505	Trending News Analyst Revision
SNY Sanofi	4.0315 of 5 stars	$43.88 -2.5%	$51.00 +16.2%	-10.9%	$109.15B	$49.35B	12.26	74,846	News Coverage
GSK GSK	2.8247 of 5 stars	$50.68 -1.6%	$53.00 +4.6%	+30.0%	$104.54B	$43.07B	13.17	66,841	Dividend Cut
TAK Takeda Pharmaceutical	3.1561 of 5 stars	$15.78 +1.1%	N/A	+4.7%	$49.65B	$28.32B	40.45	47,455

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARGX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenex (ARGX) Competitors

ARGX vs. NVO, SNY, GSK, TAK, and TEVA

How does argenex compare to Novo Nordisk A/S?

Summary

How does argenex compare to Sanofi?

Summary

How does argenex compare to GSK?

Summary

How does argenex compare to Takeda Pharmaceutical?

Summary

How does argenex compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

argenex (ARGX) Competitors

ARGX vs. NVO, SNY, GSK, TAK, and TEVA

How does argenex compare to Novo Nordisk A/S?

Is ARGX or NVO more profitable?

Which has preferable earnings and valuation, ARGX or NVO?

Which has more risk & volatility, ARGX or NVO?

Do analysts recommend ARGX or NVO?

Do institutionals & insiders have more ownership in ARGX or NVO?

Does the media favor ARGX or NVO?

Summary

How does argenex compare to Sanofi?

Does the media favor ARGX or SNY?

Which has stronger valuation and earnings, ARGX or SNY?

Do analysts recommend ARGX or SNY?

Which has more volatility & risk, ARGX or SNY?

Is ARGX or SNY more profitable?

Do institutionals and insiders have more ownership in ARGX or SNY?

Summary

How does argenex compare to GSK?

Which has preferable valuation & earnings, GSK or ARGX?

Is GSK or ARGX more profitable?

Do insiders and institutionals hold more shares of GSK or ARGX?

Which has more risk and volatility, GSK or ARGX?

Do analysts recommend GSK or ARGX?

Does the media prefer GSK or ARGX?

Summary

How does argenex compare to Takeda Pharmaceutical?

Which has more risk and volatility, ARGX or TAK?

Does the media favor ARGX or TAK?

Do analysts rate ARGX or TAK?

Do institutionals & insiders hold more shares of ARGX or TAK?

Which has better valuation & earnings, ARGX or TAK?

Is ARGX or TAK more profitable?

Summary

How does argenex compare to Teva Pharmaceutical Industries?

Which has more volatility and risk, TEVA or ARGX?

Which has stronger valuation and earnings, TEVA or ARGX?

Is TEVA or ARGX more profitable?

Do institutionals and insiders believe in TEVA or ARGX?

Do analysts rate TEVA or ARGX?

Does the media refer more to TEVA or ARGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools